Sai Parenterals to Set Up R&D Unit in Hyderabad, Acquires Majority Stake in Australian Pharma Firm
Sai Parenterals Limited has announced plans to establish a new research and development unit in Hyderabad while simultaneously upgrading its existing manufacturing facilities. The move comes as part of the company’s expansion strategy to strengthen its presence in the pharmaceutical sector.
In a significant development, the company has acquired a 74.6 percent stake in Noumed Pharma, an Australia-based pharmaceutical company, for ₹125 crore. This strategic acquisition is expected to significantly boost Sai Parenterals’ reach in global markets.
Noumed Pharma currently generates an annual revenue of AUD 60 million. The Australian firm is also in the process of constructing a new manufacturing plant, with an investment of AUD 53 million. This facility is expected to further enhance the production capabilities of the combined entity.
The acquisition marks a major milestone for Sai Parenterals as it seeks to expand its footprint beyond Indian borders. The deal provides the company with access to Noumed’s established distribution networks and customer base in Australia and other international markets.
The establishment of the R&D unit in Hyderabad aligns with the company’s commitment to innovation and development of new pharmaceutical products. Hyderabad, known as India’s pharmaceutical hub, offers a conducive ecosystem for research and development activities in the life sciences sector.
Sai Parenterals’ expansion plans are backed by prominent investment firms including Samarsh, Vyom, Blue Lotus, and Gruhas. The support from these financial partners indicates strong investor confidence in the company’s growth trajectory and business model.
The facility upgrades planned by Sai Parenterals are expected to enhance production capacity and improve manufacturing standards to meet international quality requirements. This infrastructure development is crucial for the company to serve both domestic and international markets effectively.
The pharmaceutical sector in Telangana has been witnessing significant investments in recent years, with several companies choosing Hyderabad as their preferred destination for setting up manufacturing and research facilities. Sai Parenterals’ decision to establish its R&D unit in the city further reinforces Hyderabad’s position as a leading pharmaceutical hub in India.
